| __timestamp | CymaBay Therapeutics, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 49315000 |
| Thursday, January 1, 2015 | 8871000 | 75043000 |
| Friday, January 1, 2016 | 9645000 | 83749000 |
| Sunday, January 1, 2017 | 12387000 | 122682000 |
| Monday, January 1, 2018 | 14381000 | 207761000 |
| Tuesday, January 1, 2019 | 19238000 | 284812000 |
| Wednesday, January 1, 2020 | 17425000 | 317875000 |
| Friday, January 1, 2021 | 23040000 | 282660000 |
| Saturday, January 1, 2022 | 25116000 | 451421000 |
| Sunday, January 1, 2023 | 51953000 | 481871000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, CymaBay Therapeutics, Inc. and Sarepta Therapeutics, Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, CymaBay's SG&A expenses grew by over 500%, reflecting a strategic expansion and investment in operational capabilities. In contrast, Sarepta's SG&A expenses surged by nearly 900%, indicating aggressive growth and scaling efforts.
By 2023, Sarepta's SG&A expenses were approximately nine times higher than CymaBay's, highlighting its dominant market position. This financial narrative underscores the contrasting strategies of these biotech firms, with CymaBay focusing on steady growth and Sarepta on rapid expansion. As the biotech landscape evolves, these spending patterns offer valuable insights into the strategic priorities of these industry players.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Sarepta Therapeutics, Inc.
Breaking Down SG&A Expenses: argenx SE vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs CymaBay Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Ascendis Pharma A/S
Sarepta Therapeutics, Inc. or Opthea Limited: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Lantheus Holdings, Inc.
Opthea Limited vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
CymaBay Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
CymaBay Therapeutics, Inc. vs Galapagos NV: SG&A Expense Trends